- Email: [email protected]
Good 2Q 2006 prospects for Novozymes
FOCUS
ON
C ATA LY S T S
income amounted to $29.5 M; and Fine Chemicals segment net sales were $146.2 M and segment income was $13.8 M. R&D expenses were $11.198 M during 2Q 2006 and $22.643 M during 1H 2006 ($10.342 M in 2Q 2005 and $21.322 M in 1H 2005).
construction for companies that will license Meteor. According to Dow, the agreement is the first of such kind the company has forged for the technology.
Albemarle Corp 2Q and 1H 2006 results, 24 Jul 2006 (Albemarle Corp, 330 South Fourth Street, PO Box 1335, Richmond, VA 23210, USA. Tel: +1 804 788 6000. Fax: +1 804 388 7686. Website: http://www.albemarle.com)
Kvaerner poised to land Meteor EO-EG contracts in China
CRI and hte in R&D pact Shell’s CRI/Criterion catalyst subsidiary and hte, the German highthroughput experimentation company, have launched a catalyst discovery and development programme. The companies have been cooperating on validating hte’s reactor technology and methods for discovering new ethylbenzene dehydrogenation catalysts for the production of styrene. They will now begin developing the new catalysts themselves. Chemical and Engineering News, 17 Jul 2006, 84 (29), 21-22 (Website: http://www.cen-online.org)
Degussa and Uhde sell licence German companies Degussa AG in Düsseldorf and Uhde GmbH in Dortmund jointly developed a process for the manufacture of propylene oxide from H2O2, the so-called HPPO process. Korean company SKC in Seoul has now acquired a licence for this process. SKC will start operations of a new HPPO plant with a capacity of 100,000 tonne/y at the site in Ulsan in Korea at the beginning of 2008. The company aims to meet the rising demand for propylene oxide in Asia. Kunststoffe, Jun 2006, 96 (6), 9 (in German)
Dow and Aker Kvaerner link on EO-EG process Dow Chemical and Aker Kvaerner Netherlands have entered into a cooperative agreement covering delivery of services to licencees of Dow’s Meteor process technology for conversion of ethylene oxide into ethylene glycol. Aker will work with potential licencees in the evaluation of the METEOR process technology, and will handle execution of engineering, procurement, and
SEPTEMBER 2006
Chemical Week, 5/12 Jul 2006, 168 (23), 6 & ICIS Chemical Business, 17 Jul 2006 (Website: http://icischemicalbusiness.com)
Aker Kvaerner is expected to receive two Chinese orders for ethylene oxide-ethylene glycol (EO-EG) plants based on Dow Chemical’s Meteor process. The announcement follows a cooperation deal signed by Aker Kvaerner and Dow Chemical for the supply of EO-EG units running on the Meteor technology. The Meteor process will be used by Tianjin Co for its 420,000 tonne/y EG plant in Tianjin, China. The EG unit will be part of Sinopec’s planned 1 M tonne/y ethylene complex in Tianjin. The Meteor process will also be used by Zhenhai Refining and Chemical, a subsidiary of Sinopec, for its 650,000 tonne/y EG plant in Ningbo, China. The Ningbo EG plant will be a part of Zhenhai’s proposed cracker complex at the Ningbo site. Chemical Week, 5/12 Jul 2006, 18 (23), 15
Genzyme reports 2Q 2006 financial results Genzyme Corp reported a 19% increase in 2Q 2006 revenue, driven by growth across all major product areas. Revenue rose to $793.4 M for 2Q 2006 ($668.1 M in 2Q 2005). GAAP net income increased to $134.5 M for 2Q 2006 ($123.6 M in 2Q 2005). Genzyme reiterated its full-year 2006 revenue guidance of $3.1 to $3.3 bn, its GAAP earnings guidance of $1.78$1.88/ diluted share, and its non-GAAP earnings guidance of $2.65-$2.75/ diluted share. Genzyme 2Q and 1H 2006 interim report, 12 Jul 2006 (Genzyme Corp, One Kendall Square, Cambridge, MA 02139, USA. Tel: +1 617 252 7500. Fax: +1 617 252 7600. Website: http://www.genzyme.com)
GSPI consortium plans production of 500 M gallons of biofuels Green Star Products Inc (GSPI) has finalized negotiations with a consortium of companies to produce up to 500 M gallon/y of biofuels within
five years. Additional companies have indicated they will be coming on board shortly. The GSPI consortium will construct complete BioRefinery facilities incorporating both biodiesel with adjacent ethanol production facilities. The ethanol facility will use waste agricultural products such as corn stover and switch grass. Press release from: Green Star Products Inc, 858 Third Avenue, 455 Chula Vista, CA 91911-1305, USA. Tel: +1 619 409 8977. Fax: +1 619 409 9598. E-mail: [email protected]. Website: http://www.baat.com (28 Jun 2006)
Yves Rocher renews partnership with LibraGen LibraGen has succeeded in improving the synthesis of an active ingredient of vegetable origin on Yves Rocher’s behalf. LibraGen’s biocatalysis process results in a 50-fold increase in yield. The two companies plan to continue with their partnership. LibraGen will concentrate on optimizing the bioprocess using enzymes in the presence of natural solvents. It will also be responsible for producing the first batches. Eventually it will move on to industrial scale production. Chimie Pharma Hebdo, 17 Jul 2006, (348) (Website: http://www.france-chimie.com) (in French)
Good 2Q 2006 prospects for Novozymes The Swiss investment bank is predicting good figures for Novozymes in 2Q 2006 on the basis of the favourable development for enzymes in the bioethanol area and good sales of food enzymes. The company’s share price rose by 5.1% to DKR 393 on 27 Jul 2006 and this was attributed to Novozymes’ placing significant emphasis on biofuels. Dagbladet Borsen, 25 Jul 2006 (Website: http://www.borsen.dk) (in Danish)
Novozymes wants to supply drugs industry Novozymes, Denmark, has hitherto focused on the production of enzymes for industrial purposes but also wants to become a primary supplier to drug companies. This will be achieved through a marketing agreement with Celliance and the recently approved acquisition of Delta Biotechnology, UK. For the past 4 years it has been the company’s policy to grow outside
3
ON
C ATA LY S T S
income amounted to $29.5 M; and Fine Chemicals segment net sales were $146.2 M and segment income was $13.8 M. R&D expenses were $11.198 M during 2Q 2006 and $22.643 M during 1H 2006 ($10.342 M in 2Q 2005 and $21.322 M in 1H 2005).
construction for companies that will license Meteor. According to Dow, the agreement is the first of such kind the company has forged for the technology.
Albemarle Corp 2Q and 1H 2006 results, 24 Jul 2006 (Albemarle Corp, 330 South Fourth Street, PO Box 1335, Richmond, VA 23210, USA. Tel: +1 804 788 6000. Fax: +1 804 388 7686. Website: http://www.albemarle.com)
Kvaerner poised to land Meteor EO-EG contracts in China
CRI and hte in R&D pact Shell’s CRI/Criterion catalyst subsidiary and hte, the German highthroughput experimentation company, have launched a catalyst discovery and development programme. The companies have been cooperating on validating hte’s reactor technology and methods for discovering new ethylbenzene dehydrogenation catalysts for the production of styrene. They will now begin developing the new catalysts themselves. Chemical and Engineering News, 17 Jul 2006, 84 (29), 21-22 (Website: http://www.cen-online.org)
Degussa and Uhde sell licence German companies Degussa AG in Düsseldorf and Uhde GmbH in Dortmund jointly developed a process for the manufacture of propylene oxide from H2O2, the so-called HPPO process. Korean company SKC in Seoul has now acquired a licence for this process. SKC will start operations of a new HPPO plant with a capacity of 100,000 tonne/y at the site in Ulsan in Korea at the beginning of 2008. The company aims to meet the rising demand for propylene oxide in Asia. Kunststoffe, Jun 2006, 96 (6), 9 (in German)
Dow and Aker Kvaerner link on EO-EG process Dow Chemical and Aker Kvaerner Netherlands have entered into a cooperative agreement covering delivery of services to licencees of Dow’s Meteor process technology for conversion of ethylene oxide into ethylene glycol. Aker will work with potential licencees in the evaluation of the METEOR process technology, and will handle execution of engineering, procurement, and
SEPTEMBER 2006
Chemical Week, 5/12 Jul 2006, 168 (23), 6 & ICIS Chemical Business, 17 Jul 2006 (Website: http://icischemicalbusiness.com)
Aker Kvaerner is expected to receive two Chinese orders for ethylene oxide-ethylene glycol (EO-EG) plants based on Dow Chemical’s Meteor process. The announcement follows a cooperation deal signed by Aker Kvaerner and Dow Chemical for the supply of EO-EG units running on the Meteor technology. The Meteor process will be used by Tianjin Co for its 420,000 tonne/y EG plant in Tianjin, China. The EG unit will be part of Sinopec’s planned 1 M tonne/y ethylene complex in Tianjin. The Meteor process will also be used by Zhenhai Refining and Chemical, a subsidiary of Sinopec, for its 650,000 tonne/y EG plant in Ningbo, China. The Ningbo EG plant will be a part of Zhenhai’s proposed cracker complex at the Ningbo site. Chemical Week, 5/12 Jul 2006, 18 (23), 15
Genzyme reports 2Q 2006 financial results Genzyme Corp reported a 19% increase in 2Q 2006 revenue, driven by growth across all major product areas. Revenue rose to $793.4 M for 2Q 2006 ($668.1 M in 2Q 2005). GAAP net income increased to $134.5 M for 2Q 2006 ($123.6 M in 2Q 2005). Genzyme reiterated its full-year 2006 revenue guidance of $3.1 to $3.3 bn, its GAAP earnings guidance of $1.78$1.88/ diluted share, and its non-GAAP earnings guidance of $2.65-$2.75/ diluted share. Genzyme 2Q and 1H 2006 interim report, 12 Jul 2006 (Genzyme Corp, One Kendall Square, Cambridge, MA 02139, USA. Tel: +1 617 252 7500. Fax: +1 617 252 7600. Website: http://www.genzyme.com)
GSPI consortium plans production of 500 M gallons of biofuels Green Star Products Inc (GSPI) has finalized negotiations with a consortium of companies to produce up to 500 M gallon/y of biofuels within
five years. Additional companies have indicated they will be coming on board shortly. The GSPI consortium will construct complete BioRefinery facilities incorporating both biodiesel with adjacent ethanol production facilities. The ethanol facility will use waste agricultural products such as corn stover and switch grass. Press release from: Green Star Products Inc, 858 Third Avenue, 455 Chula Vista, CA 91911-1305, USA. Tel: +1 619 409 8977. Fax: +1 619 409 9598. E-mail: [email protected]. Website: http://www.baat.com (28 Jun 2006)
Yves Rocher renews partnership with LibraGen LibraGen has succeeded in improving the synthesis of an active ingredient of vegetable origin on Yves Rocher’s behalf. LibraGen’s biocatalysis process results in a 50-fold increase in yield. The two companies plan to continue with their partnership. LibraGen will concentrate on optimizing the bioprocess using enzymes in the presence of natural solvents. It will also be responsible for producing the first batches. Eventually it will move on to industrial scale production. Chimie Pharma Hebdo, 17 Jul 2006, (348) (Website: http://www.france-chimie.com) (in French)
Good 2Q 2006 prospects for Novozymes The Swiss investment bank is predicting good figures for Novozymes in 2Q 2006 on the basis of the favourable development for enzymes in the bioethanol area and good sales of food enzymes. The company’s share price rose by 5.1% to DKR 393 on 27 Jul 2006 and this was attributed to Novozymes’ placing significant emphasis on biofuels. Dagbladet Borsen, 25 Jul 2006 (Website: http://www.borsen.dk) (in Danish)
Novozymes wants to supply drugs industry Novozymes, Denmark, has hitherto focused on the production of enzymes for industrial purposes but also wants to become a primary supplier to drug companies. This will be achieved through a marketing agreement with Celliance and the recently approved acquisition of Delta Biotechnology, UK. For the past 4 years it has been the company’s policy to grow outside
3